<DOC>
	<DOCNO>NCT01817868</DOCNO>
	<brief_summary>The project observational , multi-central , prospective , non-interventional open-label data collection study secondary prophylaxis recombinant FVIII product adolescent adult severe hemophilia A ( FVIII &lt; 1 % ) . It control observation patient secondary prophylaxis versus on-demand treatment regimen . Patients enrol preferably 1:1 basis regard prophylaxis on-demand treatment . The patient enrollment period 2 year follow-up ( observation period ) 2 year patient . Based primary effectiveness parameter ( joint bleeds overall bleeds per year ) observation period 2 year consider sufficient although admit rather short ass progression orthopedic status . Previously treat prophylaxis patient least 50 exposure day patient continue prophylaxis treatment include .</brief_summary>
	<brief_title>Comparison Efficacy , Safety Costs Recombinant FVIII Products Between On-demand Secondary Prophylaxis Groups Haemophilia A Patients</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Age â‰¥ 18 year Severe hemophilia A ( FVIII &lt; 1 % ) diagnosis Prior treatment ongoing treatment ondemand prophylaxis regimens accord Turkish guideline requirement Previously treat patient least &gt; 50 exposure day Written inform consent sign patient/legal representative Currently immune tolerance treatment Platelet count &lt; 75,000/mm3 Participation another study Existence inhibitor past last currently available blood sample prior study start ( Bethesda titer &lt; 0.6 BU/ml ) Existence inhibitor history family member also diagnose hemophilia A Having primary prophylaxis define introduction Participation another study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Hemophilia</keyword>
	<keyword>Turkey</keyword>
	<keyword>Observational</keyword>
	<keyword>Adult</keyword>
</DOC>